Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Clinical trial NCT06794073 · RECRUITING

Trial details

NCT number: NCT06794073
Sponsor: Shanghai Zhongshan Hospital
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Adenocarcinoma Digestive System Neoplasms Liver Neoplasms

Start date: 2026-01-31
Primary completion: 2026-08-31
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.